The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
CAMZYOS (Bristol-Myers Squibb Australia Pty Ltd)
Product name
CAMZYOS
Date registered
Evaluation commenced
Decision date
Approval time
195 (255 working days)
Active ingredients
mavacamten
Registration type
NCE/NBE
Indication
CAMZYOS is indicated for the treatment of adults with symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy.